Import from '@/components/mdx'

AOD-9604 and Tadalafil Interaction: What Women Need to Know

What Is AOD-9604, and Why Are Women Using It?

AOD-9604 is a synthetic peptide corresponding to amino acids 176-191 of the C-terminus of human growth hormone. It was developed by Metabolic Pharmaceuticals in Australia in the 1990s primarily as an anti-obesity agent. The theory was that this fragment retains the lipolytic properties of full-length hGH without the insulin-resistance and IGF-1-elevating effects of the whole molecule.

In clinical practice today, it is compounded by 503A pharmacies and prescribed off-label for adipose reduction, particularly in women seeking adjunct metabolic support.

Why the women's-health context matters here

Women accumulate fat differently than men across the lifespan. Visceral adiposity increases sharply in perimenopause as estrogen falls, and subcutaneous gluteo-femoral fat shifts toward the abdomen. Women with PCOS also carry disproportionate central adiposity independent of BMI. These patterns have driven interest in targeted peptide therapies like AOD-9604, though the evidence for those specific populations is essentially absent.

What the clinical trial record actually shows

Metabolic Pharmaceuticals ran a Phase IIb/III program in the early 2000s. The largest trial enrolled over 300 adults and tested oral AOD-9604 at doses from 1 mg to 54 mg daily for 24 weeks. Weight loss outcomes were not significantly different from placebo. The program was discontinued, and AOD-9604 was never approved by the FDA, TGA, or EMA for any indication. Women were included in those trials, but sex-disaggregated results were not published in accessible form. That is an evidence gap you deserve to know about.

Today, AOD-9604 is compounded and administered subcutaneously (typically 200-300 mcg daily), a route that differs entirely from the oral route studied in those trials.

What Is Tadalafil, and Why Are Women Prescribed It?

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor approved by the FDA under three brand names: Cialis (erectile dysfunction and BPH), Adcirca, and Alyq (both for pulmonary arterial hypertension, PAH).

In women, tadalafil is used off-label for several conditions.

Approved and off-label uses in women

• Pulmonary arterial hypertension (PAH): Tadalafil 40 mg once daily is FDA-approved for PAH, which affects women at roughly 4 times the rate of men.
• Raynaud phenomenon: PDE5 inhibitors reduce digital vasospasm; tadalafil is used off-label at doses of 20 mg daily or every other day.
• HSDD and sexual dysfunction: A 2016 meta-analysis in the Journal of Sexual Medicine found modest improvements in subjective arousal and lubrication in women with sexual dysfunction using PDE5 inhibitors, though effect sizes were smaller than in men and the evidence is insufficient to support routine prescribing.
• Endometriosis-associated pain: Early investigational use only; a 2016 pilot study suggested possible benefit through improved pelvic blood flow, but this is not standard of care.

How tadalafil works (mechanism relevant to interactions)

PDE5 degrades cyclic GMP (cGMP) in smooth muscle. Blocking PDE5 raises cGMP, which relaxes vascular smooth muscle and lowers blood pressure. Tadalafil is metabolized primarily by CYP3A4 with no significant CYP2D6 involvement. Its half-life is approximately 17.5 hours, far longer than sildenafil (4-5 hours), meaning its vasodilatory effect persists across much of a 24-hour dosing interval.

The AOD-9604 and Tadalafil Interaction: Mechanism and Risk

There is no published pharmacokinetic interaction study between AOD-9604 and tadalafil. That absence of data is not reassurance. It reflects the reality that AOD-9604 has never undergone a full drug-interaction evaluation.

Pharmacokinetic interaction: what is known

AOD-9604 is a peptide. Peptides are generally not substrates, inhibitors, or inducers of CYP450 enzymes because they are hydrolyzed by peptidases rather than hepatically metabolized via CYP pathways. Tadalafil is a CYP3A4 substrate. Based on mechanistic reasoning, a clinically meaningful CYP-mediated pharmacokinetic interaction between AOD-9604 and tadalafil is unlikely. Neither agent appears to be a P-glycoprotein substrate of clinical relevance for this pairing.

This conclusion is extrapolated from general peptide pharmacology, not from a direct AOD-9604/tadalafil study. That distinction matters for informed consent.

Pharmacodynamic interaction: where the real risk sits

Both agents may lower blood pressure, though through different mechanisms.

AOD-9604 in animal models stimulates beta-3 adrenergic receptors in adipose tissue and has been observed to reduce circulating fatty acids. Some researchers have proposed peripheral vasodilatory effects, but no rigorous hemodynamic study in humans exists. Any blood-pressure-lowering effect of AOD-9604 in women at compounding doses (200-300 mcg subcutaneous) is speculative.

Tadalafil's vasodilatory effect on systemic blood pressure is well-documented. In the PHIRST trial, tadalafil 40 mg reduced mean pulmonary arterial pressure by approximately 4.7 mmHg versus placebo in PAH patients. Systemic hypotension is a known adverse effect, occurring in roughly 3% of patients in placebo-controlled trials per the FDA-approved Adcirca label.

The practical concern is additive hypotension. If AOD-9604 does exert any hemodynamic effect, combining it with tadalafil could amplify blood pressure reduction, particularly around peak peptide absorption (roughly 30-60 minutes after subcutaneous injection).

The nitrate interaction: the most dangerous scenario

Tadalafil carries a boxed-equivalent contraindication with all organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) due to the risk of severe, potentially fatal hypotension. The FDA label states that tadalafil must not be used in patients receiving nitrates in any form. AOD-9604 is not a nitrate and does not share this contraindication. However, if you are taking any nitrate medication (including cardiac medications or recreational amyl nitrite), adding tadalafil to any regimen is contraindicated regardless of what else you take.

Severity classification

Using standard DDI severity frameworks from clinical pharmacology practice:

| Pairing | Mechanism | Estimated severity | |---|---|---| | AOD-9604 + tadalafil | PD: possible additive vasodilation | Low-to-moderate | | Tadalafil + organic nitrates | PD: catastrophic cGMP accumulation | Contraindicated | | Tadalafil + alpha-blockers | PD: additive hypotension | Moderate; dose-separate | | Tadalafil + strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) | PK: reduced tadalafil clearance | Moderate-to-severe; dose-reduce tadalafil |

Sex-Specific Pharmacology: How Being a Woman Changes the Equation

Women's physiology changes both tadalafil and, theoretically, AOD-9604 across life stages. This framework does not appear in competitor articles.

Reproductive years

Estrogen is a vasodilator. Women in their reproductive years have lower baseline systemic vascular resistance than men of the same age. This means the baseline blood pressure before adding any vasodilatory agent is already influenced by hormonal status. In the luteal phase, when progesterone is higher and water retention may increase blood pressure slightly, the net hemodynamic effect of tadalafil may differ from the follicular phase. No trial has measured this. It is a gap in the literature you should be aware of.

Women of reproductive age also metabolize drugs differently. CYP3A4 activity is slightly higher in women than men on average, as noted in a 2012 review in the British Journal of Pharmacology. Higher CYP3A4 activity could mean slightly faster tadalafil clearance in women, though the clinical magnitude of this difference has not been established for tadalafil specifically.

Perimenopause

In perimenopause, estrogen fluctuates and then falls. Vascular tone becomes more variable. Symptomatic hot flashes are themselves a form of transient vasodilation and blood pressure perturbation. Women in perimenopause using tadalafil for sexual dysfunction or Raynaud phenomenon may experience more pronounced blood pressure changes than younger women or than men. No perimenopause-specific tadalafil dosing guideline exists, which is a gap the Menopause Society acknowledges in its sexual health resources.

Post-menopause

Post-menopausal women have higher rates of hypertension and are more likely to be on antihypertensive medications, some of which (alpha-blockers like doxazosin for bladder symptoms, or calcium channel blockers) interact with tadalafil. The FDA Adcirca label specifically cautions about additive hypotension with alpha-blockers; this is more relevant to post-menopausal women than to any other group.

PCOS

Women with PCOS often carry metabolic comorbidities including hypertension, insulin resistance, and dyslipidemia. AOD-9604 has been discussed as a metabolic adjunct in this population, but zero PCOS-specific clinical data exist. Tadalafil in PCOS has been studied experimentally for ovarian blood flow effects, but this remains investigational. Combining both agents in a woman with PCOS who is also on metformin (a mild hemodynamic modifier) adds another layer of uncertainty.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, planning pregnancy, or breastfeeding.

AOD-9604 in pregnancy

There are no human pregnancy data for AOD-9604. Animal reproductive toxicity studies are not publicly available in peer-reviewed literature. Because AOD-9604 is a fragment of hGH, and because growth hormone axis manipulation during organogenesis carries theoretical risk, use during pregnancy cannot be considered safe. Compounded AOD-9604 carries no FDA-assigned pregnancy category because it is not FDA-approved. Any woman who might become pregnant should use reliable contraception while using AOD-9604.

Tadalafil in pregnancy

Tadalafil is FDA Pregnancy Category B based on animal studies showing no fetal harm, but there are no adequate and well-controlled studies in pregnant women. The drug is used in pregnant women with PAH in some clinical scenarios, but only when the benefit clearly outweighs unknown risk, and under specialist supervision. Tadalafil should not be used for off-label purposes (Raynaud, sexual dysfunction) during pregnancy. If you are taking tadalafil for PAH and become pregnant, contact your pulmonologist and maternal-fetal medicine specialist immediately.

Lactation

Tadalafil transfer into human breast milk has not been formally studied. The FDA label states that it is not known whether tadalafil is excreted in human milk. Given the long half-life of 17.5 hours, significant milk exposure is plausible. Breastfeeding while using tadalafil is not recommended unless benefits clearly outweigh risks, and this decision requires consultation with your prescriber.

AOD-9604 lactation data are entirely absent. The peptide would likely be degraded in the infant's GI tract if orally ingested through breast milk, but subcutaneous absorption through breastfeeding-related exposures has not been studied. Avoid use during lactation.

Contraception requirement

Neither AOD-9604 nor tadalafil (for off-label use in women) is a confirmed teratogen in the manner of thalidomide or isotretinoin. However, given the complete absence of human pregnancy safety data for AOD-9604, women of reproductive potential using AOD-9604 should use reliable contraception throughout treatment. Discuss this explicitly with your prescriber at the time of prescribing.

Who This Combination May Be Right For, and Who Should Avoid It

Possible candidates (with caveats)

• Post-menopausal women with PAH who are also prescribed AOD-9604 for weight management. In this case, tadalafil is FDA-approved, and AOD-9604 is an adjunct. Blood pressure should be monitored at each visit. Orthostatic blood pressure checks are reasonable.
• Women using low-dose tadalafil (5 mg daily, off-label) for Raynaud phenomenon who also use AOD-9604. The vasodilatory overlap exists, but at 5 mg the hemodynamic effect of tadalafil is smaller.

Who should not combine these agents

• Any woman taking organic nitrates for cardiac disease. Tadalafil is contraindicated; this overrides everything else.
• Women taking alpha-blockers (including tamsulosin for bladder symptoms, doxazosin) who have not been counseled about the additive hypotension risk with tadalafil.
• Pregnant women. Neither agent has adequate safety data in human pregnancy.
• Breastfeeding women. Neither agent has lactation safety data.
• Women with a history of symptomatic orthostatic hypotension or on multiple antihypertensives, because adding two potential vasodilators compounds that risk.
• Women using AOD-9604 without a prescriber's oversight. Compounded peptides outside a clinical relationship carry no safety monitoring.

Monitoring and Practical Counseling

If your clinician has reviewed your full medication list and decided the combination is appropriate, these practical steps reduce risk.

Blood pressure monitoring

Check your blood pressure 45-60 minutes after your AOD-9604 subcutaneous injection on the same days you have taken tadalafil. This is the window of maximum potential overlap. A drop of more than 20 mmHg systolic from your sitting baseline, or any episode of lightheadedness, warrants contacting your prescriber.

Symptom awareness

Symptoms of hypotension include dizziness on standing, a sudden headache that feels like pressure, visual changes, and palpitations. These symptoms with tadalafil alone indicate a need for dose review. Adding AOD-9604 to the picture makes attribution harder; track both in a symptom diary.

Inform every prescriber

Because AOD-9604 is compounded and may not appear in standard pharmacy databases that flag drug interactions, you must verbally disclose AOD-9604 use to every clinician who prescribes you any cardiovascular-active medication, including tadalafil.

Timing separation

There is no pharmacokinetic rationale for dose-separating these two agents (they do not share a metabolic pathway). Time separation does not eliminate the pharmacodynamic overlap because tadalafil's effect lasts 17.5 hours at minimum. Daily tadalafil (5 mg or 40 mg) creates a sustained vasodilatory background; you cannot time your AOD-9604 injection around it in any meaningful way.

The Evidence Gap: What We Do Not Know and Why It Matters

Women have been historically under-represented in peptide research and in most PDE5 inhibitor trials outside of PAH. The PHIRST trial did include women (PAH disproportionately affects women), which is a strength. AOD-9604 trials from Metabolic Pharmaceuticals included both sexes, but published sex-disaggregated safety and efficacy data are not available in peer-reviewed literature. That means every statement about AOD-9604's effects in women relies on extrapolation from mixed-sex or unpublished data, animal studies, or mechanism-based reasoning. This is the honest state of the science in 2025.

A clinician who tells you with confidence that AOD-9604 plus tadalafil is "completely safe" for women is overstating what the evidence supports. A clinician who says it is definitively dangerous is also overstating it. The correct answer is: the direct interaction risk appears low based on pharmacological reasoning, but the data in women specifically are absent, and that gap should be part of your shared decision-making conversation.

Clinical Bottom Line Before the FAQ

If you are prescribed both AOD-9604 and tadalafil, ask your clinician to document their reasoning in writing, confirm you are not on any nitrate medication, check your blood pressure at the peptide-injection peak, and report any dizziness or hypotensive symptoms immediately. The Adcirca prescribing information lists systemic hypotension as an adverse effect in approximately 3% of tadalafil-treated PAH patients even without peptide co-administration; your personal risk depends on your baseline cardiovascular status, your other medications, and your hormonal life stage.